GLP1-AD-TTE

Completed

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

GLP-1 Receptor Agonists Prevent Alzheimer's Disease Onset, Not Progression: Resolving the Real-World-Randomised Trial Paradox Across Five Continents

Lead sponsor

West China Hospital

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

213,891

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•HbA1c ≤10.5%

Primary endpoint

•Alzheimer's Disease

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07677865

Org study IDWestChinaH-HX-2026-004-GLP1-AD

Timeline

Milestones

Study start2007-01-01actual

Primary completion2024-12-31actual

Study completion2026-06-24actual

Study first posted2026-07-01actual

Last update posted2026-07-01actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age40 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults aged ≥ 40 years with type 2 diabetes (ICD-10 E11) or obesity (E66) from five EHR-linked cohorts across four continents: Optum Clinformatics (USA), Mass General Brigham Biobank (USA), CPRD Aurum (UK), Swedish National Diabetes Register (Sweden), and Hong Kong Hospital Authority CDARS (Hong Kong SAR)

Inclusion criteria

•• Age ≥ 40 years

-Diagnosis of type 2 diabetes (ICD-10 E11) or obesity (E66)

-≥ 2 years of continuous enrolment in the cohort

-Baseline HbA1c < 10.5%

-No prior diagnosis of any neurodegenerative disease

-No prior use of any GLP-1RA or DPP-4i

Exclusion criteria

•• Prior diagnosis of Alzheimer's disease or other neurodegenerative diseases

-Prior use of GLP-1 receptor agonists or DPP-4 inhibitors

-Age < 40 years

-Baseline HbA1c ≥ 10.5%

-Less than 2 years of continuous enrolment

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

5 endpoints

Primary/protocol endpoint

Incidence of Alzheimer's Disease

Time frame:Up to 10 years (from index date of medication initiation to date of first AD diagnosis, death, or end of follow-up, whichever occurs first).

event count, event

Secondary/protocol endpoint

Incidence of All-Cause Dementia.

Time frame:Up to 10 years

event count, event

Secondary/protocol endpoint

Rate of Progression from Mild Cognitive Impairment (MCI) to Alzheimer's Disease

Time frame:Up to 10 years

descriptive

Secondary/protocol endpoint

Rate of All-Cause Mortality.

Time frame:Up to 10 years.

descriptive

Other/protocol endpoint

Incidence of Four Negative Control Outcomes.

Time frame:Up to 10 years.

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.